Satellite symposium to the IX European Cancer Conference (ECCO 9), Hamburg, Germany, 14-18 September 1997. Aredia®: The once-monthly infusion for the treatment of bone metastases

Current Opinion in Oncology

Volumn 10, Issue SUPPL. 1, 1998, Pages

  Lipton, Allan ^a  

^a University Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOKINE; ETIDRONIC ACID; PAMIDRONIC ACID;

BONE METASTASIS; BONE MINERALIZATION; CONFERENCE PAPER; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 0031787754     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Abrams HL, Spiro R, Goldstein M: Metastases in carcinoma: analysis of 1,000 autopsied cases. Cancer 1950, 3:74-76.
2. Coleman RC, Rubens RD: The clinical course of bone metastases from breast cancer. Br. J Cancer 1987, 55:61-66.
3. Clain A: Secondary malignant disease of bone. Br J Cancer 1965, 19:15-29.
4. Whitehouse JMA: Site-dependent response to chemotherapy for carcinoma of the breast. J R Soc Med 1985, 78 (suppl 9):18-22.
5. Johnson AD:Pathology of metastatic tumors in bone. Clin Orthop 1970, 73:8-32.
6. Galasko CSB, Bennett A: Relationship of bone destruction in skeleton metastases to osteoclasts activation and prostaglandins. Nature 1976, 263:508-510.
7. Kanis JA: Bone and cancer: pathophysiology and treatment of metastases. Bone 1995, 17:101S-105S.
8. Mundy GR: Bone resorption and turnover in health and disease. Bone 1987, 8 (suppl1):S9-S16.
9. Mundy GR: Identifying mechanisms for increasing bone mass. J Natl Inst Health Res 1989, 1:65-68.
10. Fleisch H: Bisphosphonates: mechanism of action and clinical application. Bone Min Res 1983, 1:319-357.
11. Fleisch H: Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 1989, 116:1-28.
12. Mundy GR, Bertolini DR: Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986, 13:291-299 [Erratum, Semin Oncol 1986, 13:1xiii].
13. Kyle RA: Multiple myeloma: review of 8 69 cases. Mayo Clin Proc 1975, 50:29-40.
14. Plasmans CMT, Kuypers W, Slooff TJJH: The effect of ethanal-hydroxy-1,1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop 1978, 132:233-243.
15. Altman RD, Johnston CC, Khairi M RA, Wellman H, Serafini AN, Sankey RR: Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 1973, 289:1379-1384.
16. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990, 322:1265-1271.
17. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9:1397-1402.
18. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukaemia Group: Randomised, placebo-controlled multicentre trail of clondronate in multiple myeloma. Lancet 1992, 340:1049-1052.
19. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA: Effect of clodronate on progression of skeletal disease in multiple myelomatosis. Eur J Cancer 1995, 31A (suppl 5):S162.
20. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, et al. for the Myeloma Aredia Study Group: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488-493.
21. Siris ES, Hyman GA, Canfield RE: Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983, 74:401-406.
22. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrum T: Long-term controlled trial of bisphosphonate in patients with osteolytic bone metastases. Lancet 1983, i:146-149.
23. Paterson AHG, Powles TJ, Kanis TA, McCloskey E, Hanson J, Ashley S: Double-blind controlled trail of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:59-65.
24. Van Breukelen FJ M, Bijvoet OLM, Van Oostenom AT: Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1997, i:805-806.
25. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD: Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 1988, 58:621-625.
26. Burckhardt P, Thiebaud D, Percy L, von Fliedner V:Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 1989, 116:54-66.
27. Ette JW, Bijvoet OL, Cleton FJ, van Oosterom AT, Sleeboom HP: Osteolytic bone metastases in breast carcinoma, pathogenesis, morbidity, and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986, 22:493-500.
28. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, Hermans J, van Emmerik B, van Dam FS, van den Bos B, Bijvoet OL, Cleton FJ:The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991, 27:544-549.
29. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papaloupos ES, Sleeboom HP, et al.: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:491-498.
30. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 1994, 74:2949-2955.
31. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335:1785-1791.
32. Lipton A, Theriault R, Leff R, Gluck S, Stewart J, Costello S, Simone J, Seaman J, Knight R, Heffernan M, Reitsma D: Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg pamidronate (Aredia) infusions [abstract 531]. Proc ASCO 1997, 16.
33. Conte PF, Latreille J, Maurik L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996, 14:2522-2529.
34. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19:663-667.
35. Van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, Blijham G, Clenton FJ, vanEck-Smit BCF, Sleebom HP, Papapoulos SE: Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996, 32A:450-454.